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Abstract: 
All pyridine nitriles and esters were metalated at the position next to the directing group using 
(TMP)3CdLi in tetrahydrofuran at room temperature. 2-, 3-, and 4-Cyanopyridine were treated with 0.5 
equivalent of base for 2 h to afford, after subsequent trapping with iodine, the corresponding 3-iodo, 2-
iodo, and 3-iodo derivatives, respectively, in yields ranging from 30 to 61%. Cyanopyrazine was 
similarly functionalized at the 3 position in 43% yield. Ethyl 3-iodopicolinate and -isonicotinate were 
synthesized from the corresponding pyridine esters in 58 and 65% yield. Less stable ethyl 4-
iodonicotinate also formed under the same conditions, and was directly converted to ethyl 4-(pyrazol-1-
yl)nicotinate in a two steps 38% yield. All three ethyl iodopyridinecarboxylates were involved in a one 
pot palladium-catalyzed cross-coupling reaction/cyclization using 2-aminopyridine to afford new 
dipyrido[1,2-a:3’,2’-d]pyrimidin-11-one, dipyrido[1,2-a:4’,3’-d]pyrimidin-11-one and dipyrido[1,2-
a:3’,4’-d]pyrimidin-5-one in yields ranging from 50 to 62%. A similar cross-coupling/cyclization 
sequence was applied to methyl 2-chloronicotinate using 2-aminopyridine, 2-amino-5-methylpyridine 
and 1-aminoisoquinoline to give the corresponding tricyclic or tetracyclic compounds in 43-79% yield. 
Dipyrido[1,2-a:4’,3’-d]pyrimidin-11-one and dipyrido[1,2-a:3',4'-d]pyrimidin-5-one showed a good 
bactericidal activity against Pseudomonas aeroginosa. Dipyrido[1,2-a:2’,3’-d]pyrimidin-5-one and 
pyrido[2',3':4,5]pyrimidino[2,1-a]isoquinolin-8-one showed a fungicidal activity against Fusarium, and 
dipyrido[1,2-a:4’,3’-d]pyrimidin-11-one against Candida albicans. Ethyl 4-(pyrazol-1-yl)nicotinate and 
dipyrido[1,2-a:2’,3’-d]pyrimidin-5-one have promising cytotoxic activities, the former toward a liver 
carcinoma cell line (HEPG2) and the latter toward a human breast carcinoma cell line (MCF7). 
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Introduction 
Interest in pyridine natural products and pharmaceuticals, as well as pyridine building blocks for 
various applications such as material science, has resulted in extensive efforts on synthesis 
methodologies.
1
 The deprotonative metalation using lithium bases has been widely used as a powerful 
method for the regioselective functionalization of such substrates.
2
 Nevertheless, the incompatibility of 
lithium compounds with reactive functions or sensitive heterocycles can be a limit to their use for the 
elaboration of complex molecules. Recourse to softer magnesium bases can improve the 
chemoselectivity of deprotonation reactions, but it is to the detriment of their efficiency since a large 
excess of base has in general to be used.
3
 
The use of metal additives to get more efficient or more chemoselective bases (synergic superbases) 
has been respectively developed by Schlosser
4
 and Lochmann
5
 with LIC-KOR, mixture of butyllithium 
(LIC) and potassium tert-butoxide (KOR), and by Caubère,
6
 Gros and Fort
7
 in the pyridine series with 
BuLi-LiDMAE (DMAE = 2-dimethylaminoethoxide). More recently, other (R)n(R’)n’MLi type bases, 
but with M different from an alkali metal, have been described by different groups.
8
 By combining 
alkali additives with soft organometallic compounds, bases such as R2Zn(TMP)Li(·TMEDA) (R = 
t
Bu, 
Bu; TMP = 2,2,6,6-tetramethylpiperidino) (described by the groups of Kondo, Uchiyama, Mulvey and 
Hevia),
9
 (TMP)2Zn·2MgCl2·2LiCl
10
 and TMPZnCl·LiCl
11
 (Knochel), 
i
Bu3Al(TMP)Li (Uchiyama and 
Mulvey),
12
 Al(TMP)3·3LiCl (Knochel),
13
 (Me3SiCH2)2Mn(TMP)Li·TMEDA (Mulvey),
14
 and 
MeCu(TMP)(CN)Li2 (Uchiyama and Wheatley)
15
 have been prepared, characterized and used to 
generate functionalized aromatic compounds. 
We recently accomplished the room temperature deproto-metalation of a large range of substrates 
including sensitive heterocycles and functionalized benzenes using a newly developed lithium-
cadmium base, (TMP)3CdLi, prepared from CdCl2·TMEDA and 3 equivalents of LiTMP.
16
 If TMEDA 
is often employed in solvents of low or modest polarities to enhance the reactivity of a base
9d,e
 or to 
 4 
obtain a specific regioselectivity,
2
 it was here rather used in order to simplify the reaction protocol, 
CdCl2·TMEDA being much less sensitive to hydration than free CdCl2.
17
 
We here describe the use of (TMP)3CdLi for the functionalization of pyridine esters and nitriles. 
Ethyl iodopyridinecarboxylates thus obtained appeared as useful key synthetic intermediates for the 
synthesis of polycyclic compounds containing a dipyridopyrimidinone skeleton. Some compounds were 
evaluated for their antimicrobial and cytotoxic activity. 
Results and Discussion 
Synthetic aspects 
Due to their electrophilic functional group and to their ring prone to nucleophilic attacks, 
cyanopyridines have never been metalated at room temperature. Reactions using cyano as a group to 
direct ortho-lithiation have been reported in the benzene series from 1982,
18
 but the first example in the 
pyridine series only appeared 20 years later. Larock and coll. showed in 2002 that it was possible to 
lithiate 3-cyanopyridine using LiTMP in tetrahydrofuran (THF) at –78 °C. This result was evidenced by 
subsequent trapping with iodine to afford a 1:1 mixture of the 2- and 4-iodo compounds in a 50% total 
yield.
19
 Rault and coll. achieved in 2005 the regioselective
20
 functionalization of the other 
cyanopyridine isomers using 2 equivalents of the same hindered lithium amide in THF at –80 °C for 
0.75 h.
21
 
The deprotonation of cyanopyridines (1-3) as well as cyanopyrazine (4) was attempted using 
(TMP)3CdLi in THF (Table 1), this base being suitable to metalate benzonitrile.
16a
 Conducting the 
reaction from 2-cyanopyridine (1) using 0.5 equivalent of base at 0 °C for 2 h resulted, after quenching 
with iodine, in the formation of a mixture from which the main compound, 2-cyano-3-iodopyridine 
(5a), was isolated in 39% yield (Entry 1). When the reaction was carried out at room temperature, the 
iodide 5a formed in 30% yield, due to the more important formation of side products (Entry 2). By 
using 1 equivalent of base at room temperature, the di- and triiodide 5b,c were obtained in 28 and 20% 
yield, respectively (Entry 3). If the formation of a diiodinated compound can be rationalized as the 
 5 
result of a dimetalation, (TMP)3CdLi being able to dideprotonate substrates such as pyrazine,
16b
 
thiazole,
16a
 N-Boc pyrrole,
16a
 thiophenes
16a
 and [1,2,3]triazolo[1,5-a]pyridines,
16c
 the triiodide 5c could 
rather result from a metalation of 5b during the trapping step with iodine, as already suggested in the 
case of 3-(2-pyridyl)-[1,2,3]triazolo[1,5-a]pyridine.
16c
 
The reaction from 4-cyanopyridine (2) was then attempted using 0.5 equivalent of base at 0 °C for 2 
h; subsequent trapping with iodine afforded a mixture of 4-cyano-3-iodo- and 4-cyano-3,5-
diodopyridine (6a,b) in 30 and 20% yield, respectively (Entry 4). By performing the reaction at room 
temperature, the diiodide was not observed, but a 72:28 ratio of 4-cyano-3-iodopyridine (6a) and 
isomeric 4-cyano-2-iodopyridine (6c) was obtained instead, the latter being isolated in 44 and 10% 
yield, respectively (Entry 5). Surprisingly, carrying out the reaction with 1 equivalent of base resulted in 
the formation of the diiodide 6d under the same conditions (Entry 6). 
The results obtained with 3-cyanopyridine (3) were less disappointing. Indeed, when exposed to 0.5 
equivalent of base at room temperature for 2 h, this substrate was regioselectively metalated at the 2 
position. This was demonstrated by subsequent interception with iodine to afford the derivative 7 in 
61% yield (Entry 7). This regioselectivity is different to that previously documented by other teams 
using LiTMP in THF at low temperatures; indeed, by using the lithium amide, the metalation took 
place unregioselectively at the positions adjacent to the cyano group.
19,21a
 Such a result could be partly 
explained by the presence of a different directing group for the metalation using LiTMP than for that 
using (TMP)3CdLi; whereas a first equivalent of LiTMP adds to the cyano group in the study 
performed by Rault and coll., it does not seem to be the case with (TMP)3CdLi (Scheme 1). 
SCHEME 1. 3-Cyanopyridine (3): Comparisons of the Species Before Ring Deprotonation using LiTMP 
and (TMP)3CdLi. 
N
CN LiTMP (1 equiv)
THF, -80 °C, 0.75 h
N
LiN
N
LiTMP
LiTMP
N
CN
(TMP)3CdLi
3 3  
 6 
TABLE 1. Deprotonation of 1-4 using 
(TMP)3CdLi Followed by Trapping with I2. 
1: 2-cyanopyridine
2: 4-cyanopyridine
3: 3-cyanopyridine
4: cyanopyrazine
1) (TMP)3CdLi
(x equiv)
THF
temp., 2 h
5-8
2) I2
3) H2O
CN
N(N)
CN
N(N) I
I
I
 
entry substrate x, temp. product(s), yield(s) 
1 1 0.5, 0 °C 
N CN
I
 
5a, 39%
a 
2 1 0.5, rt 5a, 30%
b
 
3 1 1, rt 
N CN
I
I  
5b, 28%
 
   
N CN
I
I
I  
5c, 20%
 
4 2 0.5, 0 °C 
N
I
CN
 
6a, 30%
 
   
N
I
CN
I
 
6b, 20%
 
5 2 0.5, rt 6a, 44% 
   
N
CN
I 
6c, 10%
 
6 2 1, rt 
N
CN
I
I
 
6d, 51%
 
7 3 0.5, rt 
N I
CN
 
7, 61%
 
8 4 0.5, rt 
N
N
CN
I
 
8, 43%
c 
a
 Other compounds including 2-cyano-3,4-
diiodopyridine and 2-cyano-3,6-diiodopyridine were 
identified in the crude. 
b
 Other compounds including 
2-cyano-6-iodopyridine and 2-cyano-3,6-
diiodopyridine were identified in the crude. 
c
 A 
mixture of 8 and an unidentified diiodide was 
obtained in a 75:25 ratio. 
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These conditions were extended to cyanopyrazine (4) for which metalation mainly took place at the 
position next to the cyano group to furnish the iodide 8 in 43% yield (Entry 8). 
 
The compatibility of an ester function with (TMP)3CdLi in THF at room temperature has been 
recently evidenced with the possible metalation of methyl benzoate.
16a
 Using ethyl thiophene-2-
carboxylate (9) as substrate also resulted in its cadmation.
22
 After a 2 h contact with 0.5 equivalent of 
base followed by quenching with iodine, the 5-iodo derivative 10 was obtained in 77% yield (Scheme 
2). 
SCHEME 2. Functionalization of Ethyl 
Thiophene-2-carboxylate (9) using (TMP)3CdLi. 
9
1) (TMP)3CdLi
(0.5 equiv)
THF, rt, 2 h
10
2) I2
3) H2O
S
CO2Et S
CO2EtI
(77%)  
Deprotonation of ethyl pyridinecarboxylates is a much more difficult challenge due to easy 
nucleophilic attacks on their ring. In 2007, Knochel and coll. reported the magnesiation of ethyl 
isonicotinate using (TMP)2Mg·2LiCl in THF at –40 °C for 12 h to give, after trapping with iodine, the 
corresponding 3-iodo derivative in 66% yield.
23
 
The deprotonation of the different pyridine or pyridazine esters 11-14 was attempted using 
(TMP)3CdLi in THF at room temperature for 2 h, and the metalated species intercepted with iodine 
(Table 2). Conducting the reaction from ethyl picolinate (11) using 0.5 equivalent of base resulted in 
the major formation of the 3-iodo derivative 15, which was isolated in 58% yield (Entry 1). Ethyl 
isonicotinate (12) similarly furnished the 3-iodo compound 16, and the yield of 65% could be slightly 
improved to 72% using 1 equivalent of base (Entries 2,3). Surprisingly, methyl pyridazine-4-
carboxylate (13) behaved differently when submitted to 0.5 equiv of base, with a complex mixture of 
mono- and diiodides formed (Entry 4). When treated under the same conditions, ethyl nicotinate (14) 
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allowed the synthesis of the 4-iodo derivative 17 (Entry 5). The latter could not be isolated due its 
unstability over silica gel, but could be identified by NMR. It was involved without purification in a 
known copper-catalyzed reaction
24
 with pyrazole, to provide the expected derivative 18 in a two steps 
38% yield (Scheme 3). 
TABLE 2. Deprotonation of 11-14 using 
(TMP)3CdLi Followed by Trapping with I2. 
11: ethyl picolinate
12: ethyl isonicotinate
13: methyl pyridazine-4-carboxylate
14: ethyl nicotinate
1) (TMP)3CdLi
(x equiv)
THF, rt, 2 h
15-17
2) I2
3) H2O
CO2R
N(N)
CO2R
N(N)
I I
 
entry substrate x product, yield 
1 11 0.5 
N CO2Et
I
 
15, 58%
 
2 12 0.5 
N
I
CO2Et
 
16, 65%
 
3 12 1 16, 72% 
4 13 0.5 mixture -
 
5 14 0.5 
N
CO2Et
I
 
17, -
 
SCHEME 3. Synthesis of Ethyl 4-(pyrazol-1-
yl)nicotinate (18). 
14
1) (TMP)3CdLi
(0.5 equiv)
THF
rt, 2 h
18
2) I2
3) H2O
Cu2O
N
H
N
CsCO3
CH3CN
80°C, 3 d
salicylaldoxime
N
CO2Et
N
CO2Et
N
N
(38%, 2 steps)  
It was then decided to involve in the deprotonation-trapping sequence methyl pyridine-2,6-
dicarboxylate (19). By using 0.5 equivalent of (TMP)3CdLi, the 3-iodo, 4-iodo and 3,4-diiodo 
derivatives 20-22 were obtained in a 63:28:9 ratio. Whereas the main compounds 20 and 21 were 
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isolated from the mixture in 35 and 3% yield, respectively, methyl 3,4-diiodopyridine-2,6-dicarboxylate 
(22) was only identified from the NMR spectra of the crude. Turning to 1 equivalent of base resulted in 
the formation of a fourth derivative, methyl 3,5-diiodopyridine-2,6-carboxylate (23), together with the 
previous iodides. It was isolated from the 22:25:4:49 mixture of the 3-iodo, 4-iodo, 3,5-diiodo and 3,4-
diiodo compounds in a modest 14% yield (Scheme 4). 
SCHEME 4. Deprotonation of 19 using (TMP)3CdLi Followed by Trapping with I2. 
N
1) (TMP)3CdLi
(x equiv)
THF, rt, 2 h
19
2) I2
3) H2O
CO2MeMeO2C N
20
CO2MeMeO2C N
21
CO2MeMeO2C N
22
CO2MeMeO2C N
23
CO2MeMeO2C
I
I
I
I
II
x = 0.5:                        63                   /                    28                   /                     9                    /                      0
(90% conversion)     (35%)                                    (3%)
x = 1:                           22                   /                    25                   /                      4                   /                     49
(100% conversion)                                                                                                                                        (14%)  
Aiming to valorize the newly synthesized ethyl iodopyridinecarboxylates 15-17, we studied their 
reactivity in palladium-catalyzed cross-coupling reactions. Especially, as done previously on ethyl 
halogenothiophenecarboxylates,
25
 we decided to couple those compounds, as well as methyl 2-
chloronicotinate (24), with 2-aminopyridines 25-27 in order to access to polycyclic compounds 
containing a pyridopyrimidinone moiety (Scheme 5, Table 3). Indeed, the pyridopyrimidinone core is 
present in number of biologically active substances. For example, aza analogues of methaqualone
26
 and 
2-substituted-3-arylpyrido[2,3-d]pyrimidinones
27
 proved to be anticonvulsant agents whereas some aza-
quinazolinones
28
 were described as antagonists of CXCR3. Aza-tryptanthrins exhibited 
antitrypanosomal activity
29
 and inhibited Plasmodium falciparum cyclin-dependent kinases.
30
 
SCHEME 5. Synthetic Scheme for the Synthesis of Tricyclic (or Tetracyclic) Compounds. 
X
CO2Et
N
N
H2N
+
N
N
O
N
N
NH
N
CO2Et
X = Cl, I
Pd
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Optimization of the reaction conditions was conducted by coupling methyl 2-chloronicotinate (24) 
with 2-aminopyridine (25). Whereas ethyl bromothiophenecarboxylates were very sensitive to the 
reaction conditions (several cycles of evacuation-backfilling with argon were needed) and required high 
catalyst loading (7 mol.% palladium acetate and 5 mol.% Xantphos), halogenopyridinecarboxylates 
gave good results using only 3 mol.% palladium acetate and 3.5 mol.% Xantphos. Moreover, a simple 
purge of argon was sufficient. The C-N coupling followed by the intramolecular cyclization involving 
the nitrogen atom of the pyridine ring and the carbonyl moiety of the carboxylate took place at room 
temperature but in a very low yield. Turning to 55 °C and 18 h of reaction allowed the formation of the 
expected product 28 in 20% yield. Finally, the best yield (66%) was obtained conducting the reaction at 
95 °C for 24 h (Entry 1). Those conditions were then extended to the use of 2-amino-5-methylpyridine 
(26) and 1-aminoisoquinoline (27). The methylated compound 29 was obtained after only 2.5 h of 
reaction in 79% yield (Entry 2), and the tetracyclic compound 30 in a lower 43% yield (Entry 3). 
Involving the iodo esters 15-17 in the reaction similarly resulted in the formation of the tricyclic 
compounds 31-33 (Entries 4-6). Whereas 30-33 are new compounds, 28 and 29 were soon described in 
the literature;
31
 they were obtained thanks to a two-step process including Ullman reaction of 2-
halogenonicotinic acid with 2-aminopyridine-1-oxides, and subsequent intramolecular cyclization of 
the resulting 3-carboxy-2,2’-bipyridylamin-1’-oxides using PCl3. 
TABLE 3. Buchwald-Hartwig Cross-coupling of 
24, 15-17. 
24: X=Cl, R=Me, N4
15: X=I, R=Et, N1
17: X=I, R=Et, N2
16: X=I, R=Et, N3
3 mol.% Pd(OAc)2
3.5 mol.% Xantphos
1.4 equiv Cs2CO3
dioxane, 95 °C
CO2R
N N
X
N
N
O
1
2
3
4
N
H2N
28-30
31
32
3325-27  
entry substrates product, yield 
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1 24 + 25 
N N
N
O  
28, 66%
 
2 24 + 26 
N N
N
O  
29, 79%
 
3 24 + 27 
N N
N
O  
30, 43% 
4 15 + 25 
N
N
N
O  
31, 62% 
5 16 + 25 
N
N
N
O  
32, 50%
a 
6 17 + 25 
N
N
N
O  
33, 52% 
a
 For 2 steps. 
Pharmacology 
Applying the agar plate diffusion technique,
32
 the newly synthesized compounds 28-33 were screened 
in vitro for their bactericidal activity against Gram positive bacteria (Staphylococcus aureus) and Gram 
negative bacteria (Escherichia Coli and Pseudomonas aeroginosa), and for their fungicidal activity 
against Fusarium, Aspergillus niger and Candida albicans (Table 4). The compounds 32 and 33 
showed a good bactericidal activity, similar to that of ciprofloxacin, against Pseudomonas aeroginosa 
whereas 28 and 30 showed a good fungicidal activity, similar to that of nystin, against Fusarium, and 
32 against Candida albicans. 
TABLE 4. Bactericidal and fungicidal activity of the compounds 28-33, and ciprofloxacin and nystin.
a 
entry compound 
Staphylococcus 
aureus 
Escherichia 
coli 
Pseudomonas 
aeroginosa 
Fusarium 
Aspergillus 
niger 
Candida 
albicans 
1 28 19 (++) - 24 (++) 27 (+++) - 22 (++)
 
2 29 18 (++) - 19 (++) 17 (++) - 16 (++)
 
3 30 - - - 56 (++++++) 18 (++) 19 (++) 
4 31 16 (++) - - - - 18 (++) 
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5 32 17 (++) 18 (++) 25 (+++) 20 (++) - 25 (+++) 
6 33 17 (++) - 25 (+++) - - 22 (++) 
7 Ciprofloxacin +++ +++ +++    
8 Nystin    +++ +++ +++ 
a
 The diameters of zones of inhibition are given in mm. Stock solution: 5 g in 1 mL of DMF. 1 mL of stock 
solution in each hole of each paper disk. +: < 15 mm; ++: 15-24 mm; +++: 25-34 mm; ++++: 35-44 mm, etc. 
The compounds 18 and 28-33 were also tested against a human liver carcinoma cell line (HEPG2), a 
human breast carcinoma cell line (MCF7), and a cervix carcinoma cell line (HELA) (Table 5). 
Moderate cytotoxic activities were observed; the compounds 18 and 28 were found to have more 
promising activities toward HEPG2 and MCF7, respectively, compared to a reference drug 
(doxorubicin). 
TABLE 5. In vitro cytotoxic activity (IC50) of the compounds 18, 28-33, and doxorubicin against a liver 
carcinoma cell line (HEPG2), a human breast carcinoma cell line (MCF7), and a cervix carcinoma cell 
line (HELA).
a 
entry compound HEPG2 (g.mL-1) MCF7 (g.mL-1) HELA (g.mL-1) 
1 18 0.89 2.38 1.51 
2 28 1.70 0.78 1.39 
3 29 2.27 2.99 3.11 
4 30 1.77 1.73 1.09 
5 31 1.47 2.50 3.26 
6 32 1.81 2.34 2.31 
7 33 1.58 1.96 1.70 
8 Doxorubicin 0.60 0.70 0.85 
a
 IC50 is defined as the concentration which results in a 50% decrease in cell number as compared with that of 
the control structures in the absence of an inhibitor. 
Conclusion 
All pyridine nitriles and esters were metalated at the position next to the directing group using 0.5 
equivalent of (TMP)3CdLi in tetrahydrofuran at room temperature for 2 h. Subsequent trapping with 
iodine afforded the iodo derivatives in yields ranging from 30 to 65%. The ethyl 
iodopyridinecarboxylates thus obtained were then involved in a one pot palladium-catalyzed cross-
coupling reaction/cyclization using 2-aminopyridine to afford new polycyclic compounds containing a 
 13 
pyridopyrimidinone moiety, which were evaluated for their bactericidal and fungicidal activity. Some 
of the newly synthesized compounds were tested for their antitumor activity. 
Because of the toxicity of cadmium compounds,
33
 the use of other ate bases was before considered. 
Polar mixtures including alkali (or alkaline-earth metal) were ruled out because of their lack of 
compatibility with both reactive functions and sensitive aromatic heterocycles. Lithium aluminate and 
cuprate were similarly discarded, sensitive heterocycles being converted with these bases at low 
temperatures.
12,15
 The 1:1 LiTMP/(TMP)2Zn lithium-zinc combination, prepared from ZnCl2·TMEDA 
and 3 equivalents of LiTMP, allows efficient deprotonation reactions of aromatic substrates.
34
 
Nevertheless, it was not employed here because reactions using it are in general more weakly 
chemoselective,
16b
 probably due to the presence of free LiTMP. Real lithium zincates could be more 
suitable for the functionalization of heteroaromatic esters and nitriles; studies in order to identify bases 
allowing more efficient and chemoselective reactions are currently under investigation. 
Experimental Section 
General Procedure A (Deprotonation using 0.5 equiv CdCl2·TMEDA and 1.5 equiv LiTMP 
Followed by Trapping using I2). To a stirred cooled (0 °C) solution of 2,2,6,6-tetramethylpiperidine 
(0.52 mL, 3.0 mmol) in THF (5 mL) were added BuLi (1.6 M hexanes solution, 3.0 mmol) and, 5 min 
later, CdCl2·TMEDA
35
 (0.30 g, 1.0 mmol). The mixture was stirred for 10 min at 0 °C before 
introduction of the substrate (2.0 mmol). After 2 h at room temperature, a solution of I2 (0.76 g, 3.0 
mmol) in THF (5 mL) was added. The mixture was stirred overnight before addition of an aq saturated 
solution of Na2S2O3 (10 mL) and extraction with EtOAc (3 x 20 mL). The combined organic layers 
were dried over MgSO4, filtered and concentrated under reduced pressure. 
General Procedure B (Deprotonation using 1.0 equiv CdCl2·TMEDA and 3.0 equiv LiTMP 
Followed by Trapping using I2). To a stirred cooled (0 °C) solution of 2,2,6,6-tetramethylpiperidine 
(1.1 mL, 6.0 mmol) in THF (5 mL) were successively added BuLi (1.6 M hexanes solution, 6.0 mmol) 
and, 5 min later, CdCl2·TMEDA
35
 (0.60 g, 2.0 mmol). The mixture was stirred for 10 min at 0 °C 
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before introduction of the substrate (2.0 mmol). After 2 h at room temperature, a solution of I2 (1.5 g, 
6.0 mmol) in THF (5 mL) was added. The mixture was stirred overnight before addition of an aq 
saturated solution of Na2S2O3 (10 mL) and extraction with EtOAc (3 x 20 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure. 
2-Cyano-3-iodopyridine (5a).
21a
 5a was obtained according to the general procedure A starting from 
2-cyanopyridine (0.21 g), but keeping the metallation temperature at 0 °C, and was isolated after 
purification by flash chromatography on silica gel (eluent: heptane/EtOAc 80/20) as a white powder 
(0.18 g, 39%): mp 98 °C; 
1
H NMR (200 MHz, CDCl3)  7.26 (dd, 1 H, J = 8.2 and 4.6), 8.24 (dd, 1 H, 
J = 8.2 and 1.4), 8.68 (dd, 1 H, J = 4.6 and 1.4); 
13
C NMR (50 MHz, CDCl3):  117.4, 127.5, 137.9, 
138.5, 146.6, 149.4. HRMS: calcd for C6H3IN2 (M
+•
) 229.9341, found 229.9345. 
2-Cyano-6-iodopyridine was identified by its 
1
H NMR spectra (300 MHz, CDCl3):  7.49 (t, 1 H, J 
= 7.8), 7.68 (dd, 1 H, J = 7.6 and 1.0), 7.95 (dd, 1 H, J = 7.8 and 1.0). 
2-Cyano-3,4-diiodopyridine was identified by its 
1
H NMR spectra (300 MHz, CDCl3):  7.62 (d, 1 
H, J = 8.4), 7.79 (d, 1 H, J = 8.4). 
2-Cyano-3,6-diiodopyridine (5b).
21a
 5b was obtained according to the general procedure B starting 
from 2-cyanopyridine (0.21 g), and isolated after purification by flash chromatography on silica gel 
(eluent: heptane/EtOAc 90/10) as a beige powder (0.20 g, 28%): mp 140 °C; 
1
H NMR (300 MHz, 
CDCl3)  7.62 (d, 1 H, J = 8.4), 7.80 (d, 1 H, J = 8.4); 
13
C NMR (75 MHz, CDCl3):  97.7, 116.3, 
116.5, 139.1, 140.0, 147.5. HRMS: calcd for C6H3I2N2 ([M+H]
+
) 356.8386, found 356.8387. 
2-Cyano-3,4,6-triiodopyridine (5c). 5c was obtained according to the general procedure B starting 
from 2-cyanopyridine (0.21 g), and isolated after purification by flash chromatography on silica gel 
(eluent: heptane/EtOAc 90/10) as a yellow powder (0.19 g, 20%): mp 211 °C; 
1
H NMR (300 MHz, 
CDCl3)  8.39 (s, 1 H); 
13
C NMR (75 MHz, CDCl3):  113.2, 115.9, 117.0, 122.4, 139.7, 147.1. 
HRMS: calcd for C6H2I3N2 ([M+H]
+
) 482.7352, found 482.7352. 
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4-Cyano-3-iodopyridine (6a).
21a
 6a was obtained according to the general procedure A starting from 
4-cyanopyridine (0.21 g), and isolated after purification by flash chromatography on silica gel (eluent: 
heptane/EtOAc 70/30) as a beige powder (0.20 g, 44%): mp 122 °C; 
1
H NMR (200 MHz, CDCl3)  
7.52 (dd, 1 H, J = 4.8 and 0.6), 8.71 (d, 1 H, J = 5.0), 9.10 (s, 1 H); 
13
C NMR (75 MHz, CDCl3):  96.4, 
117.0, 127.1, 127.9, 148.9, 158.0. HRMS: calcd for C6H3IN2 (M
+•
) 229.9341, found 229.9345. 
4-Cyano-3,5-diiodopyridine (6b).
21a
 6b was obtained according to the general procedure A starting 
from 4-cyanopyridine (0.21 g), but keeping the metallation temperature at 0 °C, and was isolated after 
purification by flash chromatography on silica gel (eluent: heptane/EtOAc 90/10) as a beige powder 
(0.14 g, 20%): mp 153 °C; 
1
H NMR (300 MHz, CDCl3)  8.97 (s, 2 H); 
13
C NMR (75 MHz, CDCl3):  
97.3 (2C), 118.4, 134.5, 156.4 (2C). HRMS: calcd for C6H2I2N2Na ([M+Na]
+
) 378.8205, found 
378.8207. 
4-Cyano-2-iodopyridine (6c).
36
 6c was obtained according to the general procedure A starting from 
4-cyanopyridine (0.21 g), and isolated after purification by flash chromatography on silica gel (eluent: 
heptane/EtOAc 70/30) as a beige powder (46 mg, 10%): mp 76 °C; 
1
H NMR (300 MHz, CDCl3)  7.50 
(dd, 1 H, J = 5.0 and 1.4), 7.96 (t, 1 H, J = 1.4), 8.56 (dd, 1 H, J = 5.0 and 1.4); 
13
C NMR (75 MHz, 
CDCl3):  114.6, 117.8, 121.5, 124.1, 136.0, 151.3. HRMS: calcd for C6H3IN2 (M
+•
) 229.9341, found 
229.9345. 
4-Cyano-2,3-diiodopyridine (6d). 6d was obtained according to the general procedure B starting 
from 4-cyanopyridine (0.21 g), and isolated after purification by flash chromatography on silica gel 
(eluent: heptane/EtOAc 80/20) as a beige powder (0.36 g, 51%): mp 215 °C; 
1
H NMR (300 MHz, 
CDCl3)  7.84 (d, 1 H, J = 5.3), 8.08 (d, 1 H, J = 5.3); 
13
C NMR (75 MHz, CDCl3):  110.6, 119.1, 
121.0, 127.1, 133.1, 151.7. HRMS: calcd for C6H2I2N2 (M
+•
) 355.8307, found 355.8341. 
3-Cyano-2-iodopyridine (7). 7 was obtained according to the general procedure A starting from 3-
cyanopyridine (0.21 g), and isolated after purification by flash chromatography on silica gel (eluent: 
heptane/EtOAc 80/20) as a beige powder (0.28 g, 61%): mp 127 °C; 
1
H NMR (200 MHz, CDCl3)  
 16 
7.43 (dd, 1 H, J = 7.7 and 4.9), 7.82 (dd, 1 H, J = 7.7 and 2.0), 8.54 (dd, 1 H, J = 4.9 and 2.0); 
13
C 
NMR (50 MHz, CDCl3):  117.7, 119.9, 121.0, 122.5, 141.2, 152.9. HRMS: calcd for C6H3IN2 (M
+•
) 
229.9341, found 229.9345. These data are analogous to those previously described.
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2-Cyano-3-iodopyrazine (8).
37
 8 was obtained according to the general procedure A starting from 
cyanopyrazine (0.21 g), and isolated after purification by flash chromatography on silica gel (eluent: 
heptane/EtOAc 90/10) as a yellow powder (0.20 g, 43%): mp 107 °C; 
1
H NMR (300 MHz, CDCl3)  
8.54 (d, 1 H, J = 2.4), 8.65 (d, 1 H, J = 2.4); 
13
C NMR (75 MHz, CDCl3):  116.3, 120.7, 138.2, 143.2, 
147.2. HRMS: calcd for C5H2IN3Na ([M+Na]
+
) 253.9191, found 253.9192. 
Ethyl 5-iodothiophene-2-carboxylate (10). 10 was obtained according to the general procedure A 
starting from ethyl thiophene-2-carboxylate (0.31 g), and isolated after purification by flash 
chromatography on silica gel (eluent: heptane/CH2Cl2 90/10) as a yellow oil (0.43 g, 77%): 
1
H NMR 
(300 MHz, CDCl3)  1.36 (t, 3 H, J = 7.1), 4.33 (q, 2 H, J = 7.1), 7.25 (d, 1 H, J = 3.9), 7.42 (d, 1 H, J 
= 3.9). These data are similar to those described.
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13
C NMR (75 MHz, CDCl3):  14.4, 61.5, 82.6, 
134.4, 137.8, 139.8, 161.0. 
Ethyl 3-iodopicolinate (15).
38
 15 was obtained according to the general procedure A starting from 
ethyl picolinate (0.30 g), and isolated after purification by flash chromatography on silica gel (eluent: 
heptane/EtOAc 80/20) as a yellow oil (0.32 g, 58%): 
1
H NMR (200 MHz, CDCl3)  1.45 (t, 3 H, J = 
7.1), 4.47 (q, 2 H, J = 7.1), 7.11 (dd, 1 H, J = 8.2 and 4.7), 8.25 (dd, 1 H, J = 8.2 and 1.4), 8.62 (dd, 1 
H, J = 4.7 and 1.4); 
13
C NMR (50 MHz, CDCl3):  14.1, 62.1, 92.1, 126.1, 126.2, 148.2, 152.3, 165.7. 
HRMS: calcd for C8H8INO2 (M
+•
) 276.9600, found 276.9609. 
Ethyl 3-iodoisonicotinate (16).
23
 16 was obtained according to the general procedure A starting from 
ethyl isonicotinate (0.30 g), and isolated after purification by flash chromatography on silica gel (eluent: 
heptane/EtOAc 80/20) as an orange oil (0.36 g, 65%): 
1
H NMR (200 MHz, CDCl3)  1.41 (t, 3 H, J = 
7.1), 4.42 (q, 2 H, J = 7.1), 7.62 (d, 1 H, J = 4.9), 8.60 (d, 1 H, J = 4.8), 9.08 (s, 1H); 
13
C NMR (50 
 17 
MHz, CDCl3):  14.0, 62.4, 92.3, 124.3, 142.3, 149.0, 159.4, 164.9. HRMS: calcd for C8H8INO2 (M
+•
) 
276.9600, found 276.9609. 
Methyl 3-iodopyridazine-4-carboxylate. A pure fraction was isolated (eluent: heptane/EtOAc 
85/15) from the crude obtained according to the general procedure A as a yellow solid (degradation to a 
dark residue upon standing): 
1
H NMR (300 MHz, CDCl3):  7.66 (d, 1 H, J = 5.0), 9.26 (d, 1 H, J = 
5.0), 4.01 (s, 3 H); 
13
C NMR (75 MHz, CDCl3):  53.7, 77.4, 126.2, 135.3, 150.6, 164.4. 
Methyl 3,5-diiodopyridazine-4-carboxylate. A pure fraction was isolated (eluent: heptane/EtOAc 
85/15) from the crude obtained according to the general procedure A as a yellow solid (degradation to a 
dark residue upon standing): 
1
H NMR (300 MHz, CDCl3):  9.41 (s, 1 H), 4.03 (s, 3 H); 
13
C NMR (75 
MHz, CDCl3):  54.1, 97.4, 120.2, 145.6, 157.9, 165.4. 
Ethyl 4-iodonicotinate (17). 17 was obtained according to the general procedure A starting from 
ethyl nicotinate (0.30 g), but could not be purified by flash chromatography on silica gel because of its 
low stability. It was identified by NMR: 
1
H NMR (200 MHz, CDCl3)  1.42 (t, 3 H, J = 7.1), 4.14 (q, 2 
H, J = 7.1), 7.94 (d, 1 H, J = 5.3), 8.23 (d, 1 H, J = 5.3), 8.93 (s, 1 H). 
13
C NMR (50 MHz, CDCl3):  
14.1, 62.1, 106.1, 131.0, 136.2, 151.0, 152.0, 164.7. The crude was directly involved in the reactions 
giving the compounds 18 and 32. 
Ethyl 4-(pyrazol-1-yl)nicotinate (18). 18 was obtained from the crude compound 17 by adapting a 
procedure described,
24
 and was isolated after purification by flash chromatography on silica gel (eluent: 
heptane/EtOAc 70/30) as an orange oil (0.17 g, 2 steps, 38%): 
1
H NMR (300 MHz, CDCl3)  1.24 (t, 3 
H, J = 7.1), 4.31 (q, 2 H, J = 7.2), 6.50 (dd, 1 H, J = 2.4 and 1.8), 7.48 (d, 1 H, J = 5.4), 7.75 (d, 1 H, J 
= 1.5), 7.83 (d, 1 H, J = 2.7), 8.75 (d, 1 H, J = 5.1), 8.92 (s, 1H); 
13
C NMR (75 MHz, CDCl3):  14.1, 
62.1, 108.8, 117.1, 121.9, 129.5, 142.6, 145.1, 151.5, 152.9, 165.9. HRMS: calcd for C11H12N3O2 
([M+H]
+
) 218.0930, found 218.0932. 
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Methyl 3-iodopyridine-2,6-dicarboxylate (20). 20 was obtained according to the general procedure 
A starting from methyl pyridine-2,6-dicarboxylate (0.39 g), and isolated by flash chromatography on 
silica gel (eluent: heptane/CH2Cl2 80/20) as a pale orange powder (0.22 g, 35%): mp 88–90 °C; 
1
H 
NMR (300 MHz, CDCl3)  4.00 (s, 3 H), 4.01 (s, 3 H), 7.89 (d, 1 H, J = 8.1), 8.42 (d, 1 H, J = 8.1); 
13
C 
NMR (50 MHz, CDCl3):  53.3 (2C), 95.3, 127.1, 146.8, 149.6, 152.6, 164.7, 165.5. HRMS: calcd for 
C9H8INO4 (M
+•
) 320.9498, found 320.9496. 
Methyl 4-iodopyridine-2,6-dicarboxylate (21). 21 was obtained according to the general procedure 
A starting from methyl pyridine-2,6-dicarboxylate (0.39 g), and isolated by flash chromatography on 
silica gel (eluent: heptane/CH2Cl2 80/20) in 3% (18 mg) yield: 
1
H NMR (300 MHz, CDCl3)  4.02 (s, 
6H), 8.66 (s, 2H). 
13
C NMR (50 MHz, CDCl3):  53.2 (2C), 106.8, 136.9 (2C), 148.0 (2C), 163.6 (2C). 
These data are similar to those previously described.
39
 HRMS: calcd for C7H6INO2 [(M-C2H2O2)
+•
] 
262.9443, found 262.9469. 
Methyl 3,4-diiodopyridine-2,6-dicarboxylate (22). 22 formed using the general procedure A and B, 
and was identified by its NMR data: 
1
H NMR (300 MHz, CDCl3)  3.98 (s, 6H), 8.88 (s, 1H). HRMS: 
calcd for C8H5I2NO3 [(M-CH2O)
+•
] and C7H5I2NO2 [(M-C2H2O2)
+•
] 416.8359 and 388.8410, found 
416.8379 and 388.8426. 
Methyl 3,5-diiodopyridine-2,6-dicarboxylate (23). 23 was obtained according to the general 
procedure B starting from methyl pyridine-2,6-dicarboxylate (0.39 g), and isolated by flash 
chromatography on silica gel (eluent: heptane/CH2Cl2 80/20) as a beige powder (0.13 g, 14%): mp 128–
130 °C; 
1
H NMR (300 MHz, CDCl3)  3.99 (s, 6 H), 8.88 (s, 1 H); 
13
C NMR (50 MHz, CDCl3):  53.4 
(2C), 93.4 (2C), 150.6, 159.5, 164.9 (2C). HRMS: calcd for C9H7I2NO4 (M
+•
) 446.8465, found 
446.8447. 
General Procedure C for Buchwald-Hartwig Cross-coupling. A solution of Pd(OAc)2 (10 mg, 3 
mol%), Xantphos (30 mg, 3.5 mol%) and Cs2CO3 (675 mg, 1.4 equiv) was prepared under argon in 
dioxane. When the temperature reached 55 °C, the appropriate halogenopyridine (1.5 mmol, 1 equiv) 
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was added under argon and then 5 to 10 minutes later (temperature about 80 °C), the aminopyridine 
(1.8 mmol, 1.2 equiv) was finally introduced. The reaction mixture was stirred at 95 ºC for 2.5 h to 24 h 
under argon (reaction was followed by thin layer chromatography). After cooling to room temperature, 
the reaction mixture was filtered, and the cake was washed with EtOAc. The filtrate was concentrated 
under reduced pressure. 
Dipyrido[1,2-a:2’,3’-d]pyrimidin-5-one (28). 28 was obtained according to the general procedure C 
starting from methyl 2-chloronicotinate (0.26 g) and 2-aminopyridine (0.17 g), and was isolated after 
purification by chromatography on silica gel (CHCl3 as eluent) as a yellow solid (0.20 g, 66%): mp 
220-221 °C (lit.
40
 223 °C); 
1
H NMR (250 MHz, CDCl3)  6.99 (m, 1 H), 7.43 (dd, 1 H, J = 8.0 and 
4.4), 7.64-7.69 (m, 2H), 8.78 (dd, 1 H, J = 8.0 and 2.1), 8.89 (m, 1 H), 9.12 (dd, 1 H, J = 4.4 and 2.1); 
13
C NMR (62.5 MHz, CDCl3)  111.3, 113.5, 120.6, 126.7, 127.0, 135.7, 137.0, 149.8, 157.4, 157.8, 
159.7; IR (KBr)  1698, 1641, 1593, 1543, 1526, 1411 cm-1; HRMS: calcd for C11H8N3O ([M+H]
+
) 
198.0662, found 198.0668. 
8-Methyldipyrido[1,2-a:2’,3’-d]pyrimidin-5-one (29). 29 was obtained according to the general 
procedure C starting from methyl 2-chloronicotinate (0.26 g) and 2-amino-5-methylpyridine (0.19 g), 
and was isolated after purification by chromatography on silica gel (CHCl3 as eluent) as a yellow solid 
(0.25 g, 79%): mp 201-202 °C (lit.
40
 203 °C); 
1
H NMR (250 MHz, CDCl3)  2.48 (s, 3 H), 6.82 (dd, 1 
H, J = 7.5 and 1.8), 7.38 (dd, 1 H, J = 8.0 and 4.4), 7.45 (br s, 1 H), 8.74 (dd, 1 H, J = 8.0 and 2.1), 8.79 
(d, 1 H, J = 7.5), 9.08 (dd, 1 H, J = 4.4 and 2.1); 
13
C NMR (62.5 MHz, CDCl3)  21.6, 110.9, 116.5, 
120.1, 124.4, 126.0, 137.0, 147.8, 149.9, 157.7, 157.8, 159.8; IR (KBr)  1693, 1651, 1592, 1543, 1412 
cm
-1
; HRMS: calcd for C12H10N3O ([M+H]
+
) 212.0818, found 212.0826. 
Pyrido[2',3':4,5]pyrimidino[2,1-a]isoquinolin-8-one (30). 30 was obtained according to the general 
procedure C starting from methyl 2-chloronicotinate (0.26 g) and 1-aminoisoquinoline (0.26 g), and 
was isolated after purification by chromatography on silica gel (eluent: EtOAc/C6H12 70/30) as a yellow 
solid (95 mg, 43%): mp 242-244 °C; 
1
H NMR (250 MHz, CDCl3)  7.17 (d, 1 H, J = 7.8), 7.48 (dd, 1 
 20 
H, J = 8.0 and 4.5), 7.70-7.83 (m, 3 H), 8.67 (d, 1 H, J = 7.8), 8.81 (dd, 1 H, J = 8.0 and 2.1), 9.13 (dd, 
1 H, J = 4.5 and 2.1); 9.30 (d, 1 H, J = 8.0); 
13
C NMR (62.5 MHz, CDCl3)  112.8, 114.2, 121.2, 121.5, 
126.5, 127.0, 128.2, 128.9, 133.1, 133.4, 137.0, 149.1, 156.9, 157.2, 160.1; IR (KBr)  1679, 1645, 
1593, 1555, 1423 cm
-1
; HRMS: calcd for C15H10N3O ([M+H]
+
) 248.0818, found 248.0808. 
Dipyrido[1,2-a:3’,2’-d]pyrimidin-11-one (31). 31 was obtained according to the general procedure 
C starting from ethyl 3-iodopicolinate (0.42 g) and 2-aminopyridine (0.17 g), and was isolated after 
purification by chromatography on silica gel (CHCl3 as eluent) as a yellow solid (0.12 g, 62%): mp 211 
°C; 
1
H NMR (250 MHz, CDCl3)  6.94-7.00 (m, 1 H), 7.55-7.67 (m, 2 H), 7.75 (dd, 1 H, J = 8.5 and 
4.1), 8.14 (dd, 1 H, J = 8.5 and 1.5), 8.91 (dd, 1 H, J = 4.1 and 1.5), 9.00-9.04 (m, 1H); 
13
C NMR (62.5 
MHz, CDCl3)  113.1, 126.3, 127.4, 129.0, 132.5, 135.1, 135.3, 145.6, 148.2, 148.9, 157.7; IR (KBr)  
1702, 1641, 1543, 1519, 1469, 1413 cm
-1
; HRMS: calcd for C11H8N3O ([M+H]
+
) 198.0662, found 
198.0662. 
Dipyrido[1,2-a:4’,3’-d]pyrimidin-11-one (32). 32 was obtained according to the general procedure 
C starting from crude ethyl 4-iodonicotinate (general procedure A) and 2-aminopyridine (0.23 g), and 
was isolated after purification by chromatography on silica gel (eluent: CH2Cl2/Et3N 98/2) as a brown 
solid (0.20 g, 50% for 2 steps): mp 130 °C; 
1
H NMR (300 MHz, CDCl3)  6.99 (m, 1H), 7.54 (m, 2H), 
7.68 (ddd, 1H, J = 9.2, 6.5 and 1.6), 8.80 (d, 1H, J = 6.0), 8.93 (m, 1H), 9.64 (s, 1H). 
13
C NMR (75 
MHz, CDCl3)  111.9, 113.7, 119.7, 126.4, 127.2, 139.4, 151.1, 152.0, 152.7, 152.9, 158.2. HRMS: 
calcd for C11H7N3O ([M+H]
+
) 198.0667, found 198.0670. 
Dipyrido[1,2-a:3',4'-d]pyrimidin-5-one (33). 33 was obtained according to the general procedure C 
starting from ethyl 3-iodoisonicotinate (0.42 g) and 2-aminopyridine (0.17 g), and was isolated after 
purification by chromatography on silica gel (eluent: CH2Cl2/Et3N 98/2) as an orange solid (0.15 g, 
52%): mp 164 °C; 
1
H NMR (300 MHz, CDCl3)  6.96 (m, 1H), 7.59 (m, 2H), 8.14 (dd, 1H, J = 5.4 and 
0.7), 8.62 (br d, 1H, J = 5.4), 8.86 (dt, 1H, J = 7.4 and 1.2), 9.25 (br s, 1H). 
13
C NMR (75 MHz, CDCl3) 
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 113.8, 118.6, 120.2, 126.8, 127.0, 135.1, 143.1, 143.7, 149.1, 151.9, 158.3. HRMS: calcd for 
C11H7N3O ([M+H]
+
) 198.0667, found 198.0672. 
Pharmacology. Applying the agar plate diffusion technique,
32
 the compounds were screened in vitro 
for their bactericidal activity against Gram positive bacteria (Staphylococcus aureus) and Gram 
negative bacteria (Escherichia Coli and Pseudomonas aeroginosa), and for their fungicidal activity 
against Fusarium, Aspergillus niger and Candida albicans. In this method, a standard 5 mm diameter 
sterilized filter paper disc impregnated with the compound (0.3 mg/0.1 ml of DMF) was placed on an 
agar plate seeded with the test organism. The plates were incubated for 24 hours at 37 °C for bacteria 
and 28 °C for fungi. The zone of inhibition of bacterial and fungi growth around the disc was observed. 
The compounds were tested against a liver carcinoma cell line (HEPG2), a human breast carcinoma 
cell line (MCF7), and a cervix carcinoma cell line (HELA). The method applied is similar to that 
reported by Skehan et al.
41
 using 20 Sulfo-Rhodamine-B stain (SRB). Cells were plated in 96-multiwell 
plate (104 cells/well) for 24 h before treatment with the test compound to allow attachment of cell to 
the wall of the plate. Different concentrations of the compound under test (0, 1.0, 2.5, 5.0, and 10 
μg/ml) were added to the cell monolayer in triplicate wells individual dose, and monolayer cells were 
incubated with the compounds for 48 h at 37
o
C and in atmosphere of 5% CO2. After 48 h, cells were 
fixed, washed and stained with SRB stain, excess stain was washed with acetic acid and attached stain 
was recovered with Tris-EDTA buffer. Color intensity was measured in an ELISA reader, and the 
relation between surviving fraction and drug concentration is plotted to get the survival curve of each 
tumor cell line after the specified compound and the IC50 was calculated. 
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